scispace - formally typeset
S

Stephen A. Cullinan

Researcher at University of Illinois at Chicago

Publications -  14
Citations -  854

Stephen A. Cullinan is an academic researcher from University of Illinois at Chicago. The author has contributed to research in topics: Tamoxifen & Chemotherapy. The author has an hindex of 10, co-authored 14 publications receiving 853 citations.

Papers
More filters
Journal ArticleDOI

A Comparison of Three Chemotherapeutic Regimens in the Treatment of Advanced Pancreatic and Gastric Carcinoma: Fluorouracil vs Fluorouracil and Doxorubicin vs Fluorouracil, Doxorubicin, and Mitomycin

Stephen A. Cullinan, +11 more
- 12 Apr 1985 - 
TL;DR: Because of a failure to produce improved survival or palliation, unrewarded toxicity, and excessive cost, neither the FA nor FAM regimen can be recommended for the treatment of advanced pancreatic or gastric cancer.
Journal ArticleDOI

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.

Stephen A. Cullinan, +9 more
- 15 May 1990 - 
TL;DR: Neither the Mallinson regimen nor FAP can be recommended as therapy for advanced pancreatic carcinoma and any chemotherapy for this disease should remain an experimental endeavor.
Journal ArticleDOI

Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis

James N. Ingle, +11 more
- 15 Feb 1991 - 
TL;DR: The data suggest that there is a substantive therapeutic advantage for TAM plus FLU over TAM alone in elderly women with ER of 10 fmol or greater, and require confirmation in a prospective randomized trial.
Journal ArticleDOI

Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer.

James N. Ingle, +12 more
- 01 Apr 1989 - 
TL;DR: This study does not establish a significant advantage for the concurrent administration of tamoxifen with the CFP regimen, and the importance of examination of clinically important prognostic factors, even those not utilized in stratification, and consideration of these factors in covariate analysis if imbalances are present is clearly demonstrated.
Journal Article

Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin treatment.

John H. Edmonson, +6 more
- 01 Aug 1986 - 
TL;DR: Tamoxifen in this dose cannot be recommended routinely as effective secondary treatment for patients with progestin-refractory advanced endometrial carcinoma.